Illumina, Inc. $ILMN Shares Sold by Raymond James Financial Inc.

Key Points

• Raymond James Financial Inc. reduced its holdings in Illumina, Inc. by 2.6%, now owning 368,635 shares valued at approximately $29.2 million.
• Illumina's recent earnings report revealed a net margin of 29.36% and revenues of $1.06 billion, falling short of analysts' expectations.
• Analyst ratings for Illumina vary, with a consensus rating of "Hold" and a price target averaging $124.58.

Raymond James Financial Inc. trimmed its position in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 2.6% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 368,635 shares of the life sciences company's stock after selling 9,847 shares during the period. Raymond James Financial Inc. owned about 0.23% of Illumina worth $29,247,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of ILMN. Rakuten Securities Inc. boosted its holdings in Illumina by 290.3% in the 1st quarter. Rakuten Securities Inc. now owns 363 shares of the life sciences company's stock worth $29,000 after buying an additional 270 shares during the last quarter. Center for Financial Planning Inc. acquired a new stake in Illumina in the 1st quarter worth about $33,000. Fourth Dimension Wealth LLC acquired a new stake in Illumina in the 4th quarter worth about $40,000. PFS Partners LLC boosted its holdings in shares of Illumina by 400.0% during the 1st quarter. PFS Partners LLC now owns 500 shares of the life sciences company's stock worth $40,000 after purchasing an additional 400 shares during the last quarter. Finally, Golden State Wealth Management LLC boosted its holdings in shares of Illumina by 123.2% during the 1st quarter. Golden State Wealth Management LLC now owns 529 shares of the life sciences company's stock worth $42,000 after purchasing an additional 292 shares during the last quarter. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Illumina Trading Up 0.8%

ILMN traded up $0.79 during trading hours on Friday, reaching $99.96. The company's stock had a trading volume of 1,009,106 shares, compared to its average volume of 1,732,308. Illumina, Inc. has a fifty-two week low of $68.70 and a fifty-two week high of $156.66. The stock has a market cap of $15.36 billion, a PE ratio of 12.65, a P/E/G ratio of 2.25 and a beta of 1.37. The business's 50-day moving average is $99.10 and its 200-day moving average is $88.56. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.81 and a quick ratio of 1.41.

Illumina (NASDAQ:ILMN - Get Free Report) last released its quarterly earnings results on Thursday, July 31st. The life sciences company reported $1.19 EPS for the quarter, topping analysts' consensus estimates of $1.02 by $0.17. Illumina had a return on equity of 28.93% and a net margin of 29.36%.The company had revenue of $1.06 billion for the quarter, compared to analysts' expectations of $1.12 billion. During the same period in the prior year, the firm earned $0.36 earnings per share. The firm's revenue was down 4.8% compared to the same quarter last year. Illumina has set its FY 2025 guidance at 4.450-4.55 EPS. As a group, equities research analysts predict that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the company. Robert W. Baird boosted their target price on Illumina from $84.00 to $105.00 and gave the stock a "neutral" rating in a report on Monday, July 28th. Scotiabank cut Illumina from a "sector outperform" rating to a "sector perform" rating and set a $125.00 target price on the stock. in a report on Friday, July 11th. Wall Street Zen cut Illumina from a "buy" rating to a "hold" rating in a report on Saturday, August 2nd. Royal Bank Of Canada boosted their target price on Illumina from $118.00 to $126.00 and gave the stock an "outperform" rating in a report on Friday, August 1st. Finally, Barclays boosted their target price on Illumina from $85.00 to $90.00 and gave the stock an "underweight" rating in a report on Friday, August 1st. Six equities research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, Illumina presently has an average rating of "Hold" and a consensus target price of $123.17.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.